Company intelligence / Profile preview

Perspectum Diagnostics

Oxford, England, United Kingdom

Ownership: Private
Employees: ~228
Development stage: Other

Overview

Perspectum's main platform, LiverMultiScan, is FDA-cleared and CE-marked, validated in >50 clinical trials for liver disease, with data showing robust diagnostic accuracy in fibrosis, inflammation, and fat quantification. MRCP+ is FDA-cleared for quantitative AI-enabled visualization of biliary and pancreatic systems. Products are in global commercial use and clinical development for expanded indications, with ongoing studies in metabolic, oncologic, and multi-organ disease.

Therapeutic areas: OncologyInfectious DiseasesEndocrinologyGastroenterologyMetabolic Disorders
Modalities: DeviceSoftwareDigital biomarker
Industry: Medical Imaging

Partnerships

University of OxfordUK National Health Service (NHS)AWS (Amazon Web Services)UK Biobank

Beyond the preview

Go deeper on Perspectum Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perspectum Diagnostics.

Explore the full profile